Table 1.
The correlation between the PAUF associated proteins expressions with clinicopathologic characteristics of cervical cancer.
| No. | AGR2 | BRD7 | POM121 | ||||
|---|---|---|---|---|---|---|---|
| Mean Histoscore [95% CI] | p-value | Mean Histoscore [95% CI] | p-value | Mean Histoscore [95% CI] | p-value | ||
| GROUP | |||||||
| Normal | 81 | 92 [85–99] | 0.724 | 266 [256–275] | <0.001* | 228 [209–247] | <0.001* |
| Cancer | 336 | 90 [81–99] | 63 [59–68] | 144 [134–153] | |||
| AGE | |||||||
| <50 years | 203 | 94 [83–105] | 0.274 | 61 [55–67] | 0.227 | 143 [131–155] | 0.902 |
| >50 years | 133 | 84 [70–98] | 67 [59–74] | 145 [128–161] | |||
| FIGO STAGE | |||||||
| ≤IIA | 291 | 88 [79–98] | 0.346 | 64 [59–68] | 0.749 | 141 [131–152] | 0.208 |
| IB2 or IIB | 45 | 101 [76–126] | 61 [50–73] | 158 [134–183] | |||
| CELL TYPE | |||||||
| SCC | 256 | 70 [62–79] | <0.001* | 67 [62–72] | 0.004* | 148 [137–159] | 0.123 |
| AC/ASC | 80 | 154 [136–172] | 52 [44–60] | 130 [111–150] | |||
| TUMOR SIZE | |||||||
| <4 cm | 256 | 93 [83–103] | 0.267 | 64 [59–69] | 0.64 | 143 [132–154] | 0.764 |
| >4 cm | 80 | 81 [64–99] | 61 [52–71] | 146 [127–165] | |||
| LVSI | |||||||
| Negative | 202 | 99 [88–111] | 0.007* | 63 [57–69] | 0.792 | 149 [136–162] | 0.192 |
| Positive | 133 | 76 [63–89] | 64 [57–71] | 136 [122–150] | |||
| DEPTH OF INVASION | |||||||
| <50% | 108 | 103 [87–119] | 0.042* | 57 [48–65] | 0.047* | 140 [123–158] | 0.645 |
| >50% | 228 | 84 [73–94] | 66 [61–72] | 145 [134–157] | |||
| LN METASTASIS | |||||||
| Negative | 256 | 92 [82–102] | 0.438 | 63 [57–68] | 0.664 | 144 [133–155] | 0.901 |
| Positive | 80 | 84 [67–101] | 65 [56–73] | 143 [123–162] | |||
| PM INVOLVEMENT | |||||||
| Negative | 305 | 92 [82–101] | 0.218 | 62 [57–67] | 0.082 | 145 [135–155] | 0.291 |
| Positive | 31 | 74 [47–101] | 75 [61–89] | 130 [102–157] | |||
| RESECTION MARGIN | |||||||
| Negative | 323 | 91 [82–100] | 0.446 | 63 [59–68] | 0.765 | 144 [134–154] | 0.957 |
| Positive | 13 | 72 [19–124] | 67 [41–92] | 142 [82–203] | |||
| RT RESISTANCE | |||||||
| Resistant | 20 | 102 [71–134] | 0.212 | 45 [28–62] | 0.053 | 89 [62–116] | 0.001* |
| Sensitive | 113 | 81 [66–95] | 63 [56–70] | 147 [130–164] | |||
| PRIMARY TREATMENT | |||||||
| OP only | 171 | 97 [84–110] | 0.266 | 65 [59–72] | 0.704 | 143 [129–157] | 0.989 |
| OP+ RT | 70 | 75 [58–92] | 63 [52–74] | 145 [123–167] | |||
| OP + CCRT | 90 | 88 [72–104] | 60 [52–67] | 144 [127–162] | |||
| Neoadjuvant | 5 | 87 [35–139] | 53 [-9–114] | 131 [-7–268] | |||
FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous cell carcinoma; LVSI, lymphovascular space invasion; LN, lymph node; PM, parametrium; OP, operation; RT, radiotherapy; CCRT, concurrent chemoradiation.
*
Significant at the level of p < 0.05.